Featured Posts

DC Journal
What the Media Gets Wrong About Medicaid ‘Cuts’
Headlines assert that the reforms Republicans recently passed amount to a trillion-dollar cut to Medicaid. The New York Times calls this the most significant cut to federal…

Blog
Free the Economy podcast: Alcohol labels and warnings with David Clement
In this week’s episode we cover housing abundance in California, the meaning of a market economy, union privileges for government workers,…

News Release
Senate Big Beautiful Bill Contains Needed Medicaid Reforms
The Senate today voted 51 to 50 to pass the Reconciliation package known as the “One Big Beautiful Bill,” following House passage in May.
Search Posts
Letters
Coalition Letter to OIRA Re: Request for OIRA to Resolve Interagency Disagreement Concerning IQA Implementation About Medical Marijuana
The Competitive Enterprise Institute (CEI) requests that OIRA resolve a dispute between two different agencies concerning responsibility for ensuring compliance with the Information Quality Act.
Comment
Letter to OIRA Re: Request for OIRA to Resolve Interagency Disagreement Concerning IQA Implementation About Medical Marijuana
The Competitive Enterprise Institute (CEI) requests that OIRA resolve a dispute between two different agencies concerning responsibility for ensuring compliance with the Information Quality Act.
The New York Post
Politicians Are Using Omicron as an Excuse to Return to their Autocratic Ways
Since the start of the pandemic, governors around the country have often struggled to appear to be doing something to stem COVID-19, regardless of whether…
City Journal
One Size Doesn’t Fit All
In a rebuke of the Biden administration, the Fifth Circuit Court of Appeals reaffirmed its stay of the Occupational Safety and Health Administration’s (OSHA) workplace…
The New York Post
A Reality Check on How we Handle COVID-19 Risks
COVID-19 is still with us. Cases are rising in Europe and to a smaller extent in this country. But the fact that SARS-CoV-2, the virus…
National Review
What’s Taking the FDA So Long on COVID Drug Molnupiravir?
On October 1, pharmaceutical companies Merck and Ridgeback Biotherapeutics announced that their investigational oral antiviral drug Molnupiravir reduced the risk of hospitalization or death…